Innate Pharma SA
IPHA Nasdaq· Biological Products, (No Diagnostic Substances)
KIRA · Stoqly’s AI analyst, in plain words
- Innate Pharma SA had $10.2M of revenue in fiscal 2025, down 53.3% on the year before. Over five years, revenue changed −33.7% a year on average.
- Its operating margin was −599.8%, down 343.4 pts: of every 100 in sales, about −600 is left after running the business.
- Innate Pharma SA lost $55.5M in fiscal 2025.
- Free cash flow was −$59.6M in fiscal 2025, −587.4% of revenue.
Market cap
—
P/E
—
Revenue
$10.2M
Net income
−$55.5M
Free cash flow
−$59.6M
Operating margin
−599.8%
Innate Pharma SA in 30 seconds · fiscal 2025
Are sales growing?
−53.3%
No. Sales fell 53.3% last year.
Does it make a profit?
−546.1%
No. It lost money last year.
Does profit turn into cash?
−587.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
0 / 7
Weak. It passes 0 of 7 health tests.
What Innate Pharma SA does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 1, 2026
- Legal name
- Innate Pharma SA
- CIK
- 0001598599
Innate Pharma SA · IPHA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $29.2M | $60.6M | $66.7M | $21.8M | $10.2M |
| Revenue growth | −63.3% | 107.5% | 10.0% | −67.3% | −53.3% |
| Operating margin | −193.6% | −99.6% | −20.6% | −256.3% | −599.8% |
| Net income | −$62.5M | −$61.1M | −$8.2M | −$53.5M | −$55.5M |
| Net margin | −213.8% | −100.7% | −12.3% | −245.9% | −546.1% |
| Diluted EPS | −$0.78 | −$0.77 | −$0.10 | −$0.66 | −$0.62 |
| Cash | |||||
| Cash from operations | −$69.1M | −$20.1M | −$35.2M | −$7.5M | −$59.5M |
| Capital expenditure | $1.1M | $0.6M | $0.4M | $0.4M | $0.2M |
| Free cash flow | −$70.2M | −$20.7M | −$35.6M | −$7.9M | −$59.6M |
| FCF margin | −240.4% | −34.1% | −53.4% | −36.2% | −587.4% |
| Share count change | 0.8% | 0.1% | 1.0% | 0.7% | 10.5% |
| Debt and strength | |||||
| Cash and short-term investments | $118M | $89.8M | $78.0M | $69.0M | $33.0M |
| Shareholders' equity | $122M | $57.8M | $57.4M | $9.2M | −$25.5M |
| Current ratio | 1.7x | 3.4x | 3.7x | 2.6x | 1.3x |
| Interest coverage | −153.3x | −199.4x | −19.8x | −91.1x | −122.7x |
| Returns and quality | |||||
| Return on equity | −39.9% | −68.1% | −14.2% | −160.9% | — |
| Return on tangible equity | −87.2% | −108.9% | −14.4% | −583.1% | — |
| Piotroski F-score | 0 | 3 | 3 | 1 | 0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Innate Pharma SA · IPHA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001598599). Data updated October 24, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.